Intracranial Hemorrhage Pipeline Insight

DelveInsight’s, “Intracranial hemorrhage (ICH) Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Intracranial hemorrhage pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Intracranial hemorrhage Understanding

Intracranial hemorrhage Overview

Intracranial hemorrhage (ICH) is a serious and potentially life-threatening condition characterized by bleeding within the cranial cavity, including the brain tissue and surrounding meningeal spaces. It is broadly classified into four types: epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage (SAH), and intraparenchymal hemorrhage. Epidural and subdural hemorrhages are extra-axial bleeds occurring outside the brain tissue, while SAH and intraparenchymal hemorrhage are intra-axial bleeds involving spaces within or around the brain. Epidural hemorrhage is typically caused by traumatic skull fractures leading to arterial bleeding, whereas subdural hemorrhage commonly results from rupture of bridging veins following acceleration-deceleration injuries. SAH involves bleeding into the subarachnoid space and may be traumatic or non-traumatic, with aneurysmal rupture being a major cause of non-traumatic cases. Intraparenchymal hemorrhage refers to bleeding within the brain tissue and can arise from conditions such as hypertension, arteriovenous malformations, cerebral amyloid angiopathy, aneurysm rupture, tumors, coagulopathies, infections, vasculitis, or trauma. Given the diverse etiologies and clinical presentations of ICH, prompt diagnosis using advanced imaging modalities such as CT and MRI is essential for treatment planning and disease monitoring. Management often requires surgical intervention to evacuate hematomas or relieve intracranial pressure, alongside coordinated multidisciplinary care involving neurologists, neurosurgeons, critical care specialists, and rehabilitation teams to optimize patient outcomes.

Intracranial hemorrhage (ICH) results from a combination of vascular, genetic, pharmacological, and lifestyle-related factors that weaken cerebral vessels or impair hemostasis. Hypertension is the leading modifiable risk factor, while cerebral amyloid angiopathy (CAA) is a major cause of spontaneous hemorrhage in older adults. Other contributors include excessive alcohol consumption, low serum cholesterol levels, ApoE genetic variants, anticoagulant therapy, and sympathomimetic drug use such as cocaine. These factors promote vascular fragility, coagulation abnormalities, and hemodynamic stress, collectively increasing the risk of cerebral vessel rupture and intracranial bleeding.

The pathophysiology of intracranial hemorrhage (ICH) involves bleeding into the epidural, subdural, subarachnoid, or intraparenchymal spaces following vessel rupture caused by trauma, hypertension, aneurysms, vascular malformations, or coagulation disorders. Epidural hemorrhage is commonly associated with skull fractures and arterial injury, while subdural hemorrhage typically results from tearing of bridging veins after head trauma. Subarachnoid hemorrhage most often arises from traumatic injury or rupture of an intracranial aneurysm, driven by hemodynamic stress and inflammation that weaken arterial walls. Intraparenchymal hemorrhage is primarily linked to chronic hypertensive damage to cerebral vessels, although other vascular and structural abnormalities may contribute. Regardless of subtype, vessel rupture leads to hematoma formation, increased intracranial pressure, cerebral ischemia, and secondary brain injury.

The diagnosis of intracranial hemorrhage (ICH) requires prompt clinical assessment, neurological evaluation, laboratory testing, and urgent neuroimaging to confirm the presence, subtype, and cause of bleeding. Initial evaluation focuses on airway, breathing, circulation, and neurological status, with the Glasgow Coma Scale (GCS) serving as a key tool for assessing injury severity and guiding management. Laboratory investigations, including complete blood count, coagulation profile, and metabolic panels, help identify coagulopathies, thrombocytopenia, anemia, or metabolic abnormalities that may influence outcomes. Non-contrast CT is the first-line imaging modality for rapidly detecting and characterizing hemorrhage, while CT angiography, MR angiography, or digital subtraction angiography may be used to identify underlying vascular abnormalities such as aneurysms or arteriovenous malformations. MRI provides additional value in subacute or chronic cases and in detecting secondary causes, including tumors or cavernous malformations. Together, these diagnostic approaches enable timely diagnosis, etiological assessment, and treatment planning.

The treatment of intracranial hemorrhage (ICH) focuses on rapid stabilization, prevention of hematoma expansion, control of intracranial pressure, correction of coagulopathies, and reduction of secondary brain injury. Management varies by hemorrhage subtype and may include close monitoring, blood pressure control, reversal of anticoagulation, and neurosurgical intervention. Epidural and significant subdural hematomas often require surgical evacuation, while aneurysmal subarachnoid hemorrhage is treated with surgical clipping or endovascular coiling alongside measures to prevent rebleeding and vasospasm. Intraparenchymal hemorrhage management emphasizes blood pressure control, neuroprotection, and selective surgical treatment. Prompt multidisciplinary care is critical to improving clinical outcomes and survival.

"Intracranial hemorrhage Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intracranial hemorrhage pipeline landscape is provided which includes the disease overview and Intracranial hemorrhage treatment guidelines. The assessment part of the report embraces, in depth Intracranial hemorrhage commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intracranial hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Intracranial hemorrhage Pipeline Report Highlights

The Intracranial hemorrhage companies and academics are working to assess challenges and seek opportunities that could influence Intracranial hemorrhage R&D. The therapies under development are focused on novel approaches to treat/improve Intracranial hemorrhage.

Intracranial hemorrhage Emerging Drugs Analysis

This segment of the Intracranial hemorrhage report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Intracranial hemorrhage Emerging Drugs

GTX-104: Grace Therapeutics, Inc.

GTX-104 is a clinical-stage, novel formulation of nimodipine being developed for IV infusion. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine. This nimodipine injectable formulation is comprised of a nimodipine base, an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection. GTX-104 is an aqueous solution substantially free of organic solvents, such that the nimodipine is contained in a concentrated injection solution, suspension, emulsion, or complex as a micelle, a colloidal particle, or an inclusion complex, and the formulation is stable and clear. GTX-104 has been administered in over 150 healthy volunteers and was well tolerated, with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine. Currently, the drug is in the Phase III stage of its development for the treatment of aneurysmal subarachnoid hemorrhage.

BIOX-101: Bioxodes

BIOX-101 is a proprietary recombinant protein derived from a naturally occurring molecule found in the saliva of the tick (Ixodes ricinus), developed to address the secondary complications of hemorrhagic stroke, including ischemia, neuroinflammation, and neuronal injury. Unlike traditional anticoagulants, it reduces clotting without increasing bleeding risk by selectively inhibiting Factors XIa and XIIa in the intrinsic coagulation pathway. The therapy also exerts anti-inflammatory effects by preventing neutrophil activation and the formation of NETs, which are associated with excessive inflammation, edema expansion, and blood-brain barrier disruption. This dual mechanism positions BIOX-101 as a differentiated therapeutic candidate for stroke management. Bioxodes has reported positive Phase IIa proof-of-concept data in intracerebral hemorrhage patients and is preparing for an adaptive Phase II trial in ICH.

CX213: Cenyx Biotech

CX213 is a first-in-class treatment for SAH with a novel mechanism of action. CX301 is the second ceria-based nanozyme pipeline, an innovative therapy for MIS. The product has strong potential to become a first-in-class medication for other disorders associated with ROS burst and acute inflammation. CX213 targets the root cause of acute inflammatory response, referred to as ROS; unlike currently available antioxidants that can only remove specific types of ROS, CX213 and CX301 simultaneously eliminate all types of ROS. According to the company, currently, the drug is in the Phase I stage of development for the treatment of subarachnoid hemorrhage.

Further product details are provided in the report……..

Intracranial hemorrhage Drug Therapeutic Assessment

This segment of the report provides insights about the different Intracranial hemorrhage drugs segregated based on following parameters that define the scope of the report, such as:

Major Intracranial hemorrhage Players in Intracranial hemorrhage

There are approx. 10+ key companies which are developing the therapies for Intracranial hemorrhage. The companies which have their Intracranial hemorrhage drug candidates in the most advanced stage, i.e. Phase III include, Grace Therapeutics.

Intracranial hemorrhage Clinical Trial Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Intracranial hemorrhage Drug Route of Administration

Intracranial hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Intracranial hemorrhage Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Intracranial hemorrhage Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Intracranial hemorrhage Clinical Trial Activities

The Intracranial hemorrhage pipeline report provides insights into different Intracranial hemorrhage clinical trials within Phase III, II, I, preclinical and discovery stage. It also analyses Intracranial hemorrhage therapeutic drugs key players involved in developing key drugs.

Intracranial hemorrhage Pipeline Development Activities

The Intracranial hemorrhage clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging intracranial hemorrhage drugs.

Intracranial hemorrhage Pipeline Report Insights

• Intracranial hemorrhage Pipeline Analysis
• Intracranial hemorrhage Therapeutic Assessment
• Intracranial hemorrhage Unmet Needs
• Impact of Intracranial hemorrhage Drugs

Intracranial hemorrhage Pipeline Report Assessment

• Intracranial hemorrhage Pipeline Product Profiles
• Intracranial hemorrhage Therapeutic Assessment
• Intracranial hemorrhage Pipeline Assessment
• Intracranial hemorrhage Inactive drugs assessment
• Intracranial hemorrhage Market Unmet Needs

Key Questions Answered In The Intracranial hemorrhage Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Intracranial hemorrhage drugs?
• How many Intracranial hemorrhage drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intracranial hemorrhage?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intracranial hemorrhage therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intracranial hemorrhage and their status?
• What are the key designations that have been granted to the emerging drugs?

Intracranial hemorrhage Key Players

• Grace Therapeutics, Inc.
• Bioxodes
• Cenyx Biotech
• Tiziana Life Sciences
• Qanatpharma AG

Intracranial hemorrhage Key Products

• GTX-104
• BIOX-101
• CX213
• Foralumab
• Research Program